|European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013|
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013
|Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL …|
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
|International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts|
H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ...
Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015
|Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition|
D Cardinale, A Colombo, MT Sandri, G Lamantia, N Colombo, M Civelli, ...
Circulation 114 (23), 2474-2481, 2006
|Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia|
HM Kantarjian, DJ DeAngelo, M Stelljes, G Martinelli, M Liedtke, W Stock, ...
New England Journal of Medicine 375 (8), 740-753, 2016
|Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy|
D Cardinale, MT Sandri, A Colombo, N Colombo, M Boeri, G Lamantia, ...
Circulation 109 (22), 2749-2754, 2004
|Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project|
M Federico, M Bellei, L Marcheselli, S Luminari, A Lopez-Guillermo, ...
Journal of Clinical Oncology 27 (27), 4555-4562, 2009
|Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML|
AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ...
New England Journal of Medicine, 2019
|Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly× 4 …|
M Ghielmini, SFH Schmitz, SB Cogliatti, G Pichert, J Hummerjohann, ...
Blood 103 (12), 4416-4423, 2004
|Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia|
G Bucaneve, A Micozzi, F Menichetti, P Martino, MS Dionisi, G Martinelli, ...
New England Journal of Medicine 353 (10), 977-987, 2005
|BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European …|
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...
Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011
|Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy|
D Cardinale, MT Sandri, A Martinoni, A Tricca LabTech, M Civelli, ...
Journal of the American College of Cardiology 36 (2), 517-522, 2000
|Platelet gel for healing cutaneous chronic wounds|
G Crovetti, G Martinelli, M Issi, M Barone, M Guizzardi, B Campanati, ...
Transfusion and Apheresis Science 30 (2), 145-151, 2004
|Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia|
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ...
Clinical Cancer Research 12 (24), 7374-7379, 2006
|Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia|
Italian Cooperative Study Group on Chronic Myeloid Leukemia
New England Journal of Medicine 330 (12), 820-825, 1994
|Resting and activated endothelial cells are increased in the peripheral blood of cancer patients|
P Mancuso, A Burlini, G Pruneri, A Goldhirsch, G Martinelli, F Bertolini
Blood, The Journal of the American Society of Hematology 97 (11), 3658-3661, 2001
|Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group|
E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ...
Journal of Clinical Oncology 21 (1), 20-27, 2003
|Very young women (< 35 years) with operable breast cancer: features of disease at presentation|
M Colleoni, N Rotmensz, C Robertson, L Orlando, G Viale, G Renne, ...
Annals of Oncology 13 (2), 273-279, 2002
|Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results|
HM Kantarjian, FJ Giles, KN Bhalla, J Pinilla-Ibarz, RA Larson, ...
Blood, The Journal of the American Society of Hematology 117 (4), 1141-1145, 2011
|ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression …|
S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ...
Journal of clinical oncology 23 (18), 4100-4109, 2005